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Pancreatic ductal adenocarcinoma (PDAC) harbors
the worst prognosis of any common solid tumor,
and multiple failed clinical trials indicate therapeutic
recalcitrance. Here, we use exome sequencing
of patient tumors and find multiple conserved ge-
netic alterations. However, the majority of tumors
exhibit no clearly defined therapeutic target. High-
throughput drug screens using patient-derived cell
lines found rare examples of sensitivity to monother-
apy, with most models requiring combination ther-
apy. Using PDX models, we confirmed the effective-
ness and selectivity of the identified treatment
responses. Out of more than 500 single and combi-
nation drug regimens tested, no single treatment
was effective for the majority of PDAC tumors, and
each case had unique sensitivity profiles that could
not be predicted using genetic analyses. These
data indicate a shortcoming of reliance on genetic
analysis to predict efficacy of currently available
agents against PDAC and suggest that sensitivity
profiling of patient-derived models could inform
personalized therapy design for PDAC.
INTRODUCTION
Aprecision approach to cancermedicine is transforming theway
in which cancer is treated (Aronson and Rehm, 2015; Biankin
et al., 2015). Conventionally, this approach relies on the use of
markers to define a treatment strategy for a given disease. ThereCell Re
This is an open access article under the CC BY-Naremultiple successes attributed to precisionmedicine, from the
current paradigm for breast cancer treatment stratification
based on immunohistochemical markers (e.g., estrogen recep-
tor [ER], progesterone receptor [PR], or human epidermal growth
factor receptor 2 [HER2]) to the integrated genetic analysis of
lung cancer that reveals multiple targets for therapeutic interven-
tion (e.g., ALK [anaplastic lymphoma kinase] rearrangements or
EGFR [epidermal growth factor receptor] mutations) (Deluche
et al., 2015; Lindeman et al., 2013). Based on these and other
successes, multiple clinical trials utilizing genetic information to
guide patient treatment are open.
Pancreatic ductal adenocarcinoma (PDAC) harbors a particu-
larly poor prognosis, and even after resection, long-term survival
remains poor due to the frequent recurrence as metastatic dis-
ease (Almhanna and Philip, 2011; Kleger et al., 2014; Paulson
et al., 2013; Yeo et al., 1995). Current systemic treatment of
PDAC is dependent on chemotherapy, with minimal success of
targeted approaches in the clinic. This therapeutic recalcitrance
of PDAC is surprising, given substantial pre-clinical investigation
and multiple provocative findings that would be expected to
yield clinical benefit. This disconnect between preclinical testing
and clinical outcomes suggests that more relevant models will
be important for making significant inroads into the treatment
of PDAC and that some form of patient stratification will be
required to yield improved outcome. Notably, exceptional re-
sponses to therapy do occur in patients with PDAC (Garrido-La-
guna et al., 2015), but these represent a very small segment of
the treated population.
To date, pancreatic cancer has largely failed to benefit from
the promise of precision therapy. In spite of substantial genetic
analyses (Bailey et al., 2016; Collisson et al., 2011; Jones et al.,
2008; Waddell et al., 2015; Witkiewicz et al., 2015), the path for
the treatment of the majority of PDAC cases remains obscure.ports 16, 2017–2031, August 16, 2016 ª 2016 The Author(s). 2017
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Pancreatic cancer is driven by KRAS, which is currently consid-
ered a non-actionable target. Additionally, most pancreatic tu-
mors harbor genetic lesions in multiple oncogenic pathways
(e.g., MYC amplification) or tumor-suppressive pathways (e.g.,
SMAD4 loss) that make it unclear how targeting a single genetic
event would yield therapeutic benefit. Thus, the nature and
complexity of tumor genetics in pancreatic cancer represent
the major impediments to precision treatment.
Here, we use an integrated collection of patient-derived cell
lines and xenografts that recapitulate the genetics and biology
of PDAC to identify and validate patient-selective therapeutic
sensitivities. This approach bypasses the bottleneck of requiring
genetic targets for therapeutic intervention and revealedmultiple
unique combinatorial approaches to target individual tumors.
RESULTS
Pipeline for Genetic and Functional Analysis
A pipeline was developed, wherein patients with resectable
PDAC were consented to the collection of tumor tissue, genetic
studies, and development of models (Figures 1A and 1B).
Primary tumors, patient-derived cell lines, and PDX models
were characterized by exome sequencing and exhibited a
high level of genetic conservation with the primary (E.S.K.,
U.B., C.E., C. Moxom, J. Mansour, W.C., E.M.O., and A.K.W.,
unpublished data). Cell models were used to define therapeutic
sensitivities, and selected treatments were subsequently vali-
dated in the context of the PDX originating from same primary
tumor. From the genetic analysis, more than 1,000 tumor-spe-
cific genetic events were identified, many of which impacted
on cancer-relevant pathways that are known to be disrupted in
PDAC (Figure 1C).
Patient Models Can Inform Genetic-Driven Therapeutic
Sensitivity in PDAC
A main precept of precision oncology is that genetic analysis of
the tumor will inform therapeutic options. However, from muta-
tional events identified in the 28 cases, only a handful repre-
sented targets for therapeutic intervention. Additionally, many
of the potentially actionable alleles represented variants of un-
known significance. In this setting, the availability of patient-Figure 1. Genetic Interrogation of PDAC Models
(A) Schematic of the overall pipeline used. Tumor tissue not required for diagnosis
development of PDX and cell-line models. Models were utilized to evaluate drug
(B) Summary of the models generated from PDAC cases as used in the study.
(C) Overall distribution of genetic events targeting oncogenic pathways in PDA
previously been published.
(D) Summary of models harboring the indicated genetic alterations in chromatin
(E) The indicated models were treated with increasing doses of GSK126 (0, 10, 20
mean and SD shown. Data are statistically significant, as determined by unpaire
(F) The levels of H3K27-Me3 were determined in the indicated models; total hist
(G) The presence of aberrant mitosis and basal levels of DNA damagewere determ
gH2AX staining, respectively. Representative images are shown. The scale bar fo
scale bar for gH2AX staining represents 50 mm. The EMC93 case has a mutation
(H) The EMC93 PDX was randomized for treatment with either vehicle control (n
function of time. Mice were sacrificed when controls became moribund. The diff
Error bars indicate mean ± SD.
(I) Representative images showing confluent necrosis and aberrant nuclei in trea
100 mm), gH2AX, and mitotic aberrations were detected by immunohistochemisderived models provided a unique opportunity to assess the
impact of a given allele on therapeutic sensitivities.
Chromatin remodelingSWI/SNF (switch/sucrose non-ferment-
able) complex genes (e.g., ARID1A, PBRM1, and SMARCA4) are
mutated in up to 20%of PDAC, and recent studies indicated that
SWI/SNF deficiency results in sensitivity to EZH2 inhibition (Bitler
et al., 2015; Kim et al., 2015). Two cell models exhibited genetic
alterations in the ARID1A chromatin remodeling gene, and one
harbored a SMARCA2 deletion (Figure 1D). The models were
treated with the EZH2 inhibitors GSK126 and GSK343, and sur-
vival was determined (Figures 1E and S1). Surprisingly, the
EMC7310 model that was wild-type for chromatin modifiers
was themost sensitive toEZH2 inhibitors,whilemodelsharboring
mutations in chromatin remodelers had intermediate sensitivities
(Figures 1E and S1). This marked sensitivity could be due to the
presence of high-levels of H3 K27-Me3 in the EMC7310 cell line
(Figure 1F) and/or other genetic features of the model (e.g.,
MYC amplification or RB [retinoblastoma] loss). However, these
data underscore the challenge of targeting specific genetic
events occurring in complex cancer genomes and the need to
functionally assess therapeutic sensitivities.
Another case exhibited mutation of the STAG2 gene on the
X chromosome in the primary tumor and resultant PDX model.
This event can compromise mitotic fidelity and elicit sensitivity
to DNA cross-linking agents (Evers et al., 2014; Solomon
et al., 2011). Consistent with STAG2 deficiency, the PDX ex-
hibited significant nuclear pleomorphism, mitotic aberrations,
and high baseline DNA damage relative to other PDX models
(Figure 1G). Consequently, treatment with mitomycin C signifi-
cantly restricted tumor growth in this model (Figure 1H). This
response was marked by extensive DNA damage and evidence
of mitotic catastrophe (Figure 1I). Thus, in rare circumstances,
the genetics of an individual pancreatic tumor could inform
treatment.
Patient-Derived Cell Lines Define Selective Therapeutic
Vulnerabilities
The relatively low frequency of clear, genetically encoded vulner-
abilities, combined with the complexity surrounding many
genetic variants, makes predicting therapeutic sensitivities in
PDAC difficult. In recognition of this challenge, and to definewas used for characterization of the patient tumor. Parallel tissue was used for
sensitivities that could then inform genetic or empirically defined sensitivities.
C cases used in this study (green color bar), relative to 109 cases that have
modifiers.
, and 40 mM). Data are from greater than four independent measures, with the
d t test. ***p < 0.001.
one levels were utilized for loading control.
ined by immunohistochemical analysis with pSer10-Histone H3 (pS10-H3) and
r the hematoxylin and pSer10-Histone H3 staining represents 100 mm, while the
in STAG2.
= 4) or mitomycin C (n = 7). Tumor volume was determined by calipers as a
erence in tumor volume was statistically significant as determined by ANOVA.
ted tumors (scale bar, 100 mm). Increased cleaved caspase-3 (CC3; scale bar,
try (scale bars, 50 mm).
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therapeutic vulnerabilities in the majority of tumors that do not
harbor actionable genetic events, a drug sensitivity screen with
a library of 305 agents (Data S1) was used against the patient-
derived cell lines we developed and the established PDAC cell
lines. The drug panel included compounds that are in clinical
use or advanced development and target multiple aspects of tu-
mor biology (e.g., cell cycle, apoptosis, growth factor signaling
pathways). For each cell line, early and late passage cultures
were evaluated and showed marked conservation of drug sensi-
tivities (Figure 2A; Figure S2). Cell lines developed directly from
the primary tumor or from PDX established from the same pri-
mary tumor clustered together, indicating preservation of thera-
peutic responsiveness across derivative models (Figure 2B). 59
patient-derived cell-line models were screened in total at a
dose range of 100 nM–1 mM, and area under the curve (AUC)
was calculated per drug per cell line (range = 0.08–4.95) (Data
S1). Among the 305 drugs screened, 76 drugs with an AUC
<1.5 in at least one model were identified as hits and were clus-
tered based on Euclidian distance (Figure 2C). The data showed
that similar targeted agents cluster together, indicating that there
are intrinsic sensitivities to specific pathways (e.g., MEK [MAPK/
ERK kinase] or EGFR) inhibition or chemotherapy. Unsupervised
clustering of models and affinity propagative clustering showed
that established cancer cell lines had distinct sensitivities
compared to primary models (Figures 2C and S2). In general,
established cell line models were significantly more sensitive
to chemotherapy agents (i.e., gemcitabine, pemetrexed, and
docetaxel), and one targeted agent (mubritinib) was selectively
effective in these cell lines (Figure 2D). Across the panel,
primary patient-derived cell lines exhibited a highly variable res-
ponse to treatment with selected models markedly inhibited by
targeted therapies. For example, one of the models was excep-
tionally sensitive to multiple MEK inhibitors (Figures 2E and 2F),
while others had selective sensitivity to EGFR or tyrosine kinase
inhibitors (Figure S2).
Patient Models Define Exceptional Responses to
Therapeutic Agents
Identifying exceptional responses to therapy has become one of
the critical approaches in defining targeted means to treat PDAC
and other therapy-recalcitrant diseases. Although MEK inhibi-
tors had limited single-agent antitumor activity in clinical trials
conducted in unselected PDAC patients, there has been evi-
dence for exceptional response in patients with metastatic
disease (Garrido-Laguna et al., 2015). Through detailed dose-Figure 2. PDAC Cell Lines Reveal Disparate Sensitivity to Cancer Drug
(A) Early- and late-passage cell lines were subjected to drug screening. Regres
remained highly correlated.
(B) Spearman correlation analysis of multiple cell lines derived from the samemod
drugs relative to other established pancreatic cancer models.
(C) Heatmap of primary cell lines (gray) and established cell lines (black) clustered
indicated.
(D) Drug sensitivities that were statistically different between patient-derived and e
determined by t test. Error bars indicate mean ± SD. **p < 0.01; ***p < 0.001.
(E) The AUC of drug response to the indicated MEK inhibitors was used to cluster
sensitivity to these agents.
(F) Dose-response analysis from EMC828 versus EMCT2 cell line models treated
(n = 3). The difference in response between EMC828 and EMCT2 was statisticalresponse analysis, we found that the EMC828 model was sensi-
tive to low-doseMEK inhibition (Figure 3A). In general, resistance
to MEK inhibitors is associated with compensatory activation of
AKT signaling (Mirzoeva et al., 2009; Pettazzoni et al., 2015). The
exceptional sensitivity to MEK inhibitor was associated with a
failure to engage the upregulation of AKT, and AKT activity was
actually suppressed upon treatment with MEK inhibition in this
model (Figure 3B). RNA sequencing revealed that the excep-
tional response to MEK inhibition was associated with an
enrichment of genes involved in cell adhesion, epithelial versus
mesenchymal differentiation, and KRAS dependence signature
(Singh et al., 2009). This signature was significantly enriched in
the EMC828model versus the less sensitive cell lines (Figure 3C).
The sensitivity to MEK inhibition was associated with both inhibi-
tion of cell-cycle progression and the induction of apoptosis that
translated into overall suppression of viability in clonal assays
and 3D organoid cultures (Figures 3D–3F). Since MEK inhibition
typically exerts a cytostatic effect, these data reinforced the
concept that this select tumor would be highly sensitive to
MEK inhibition. The PDX model developed from the same pri-
mary tumor was subjected to treatment with the MEK inhibitor
AZD6244 (Figures 3G and 3H). Treatment resulted in marked
suppression of tumor growth. Importantly, this response was se-
lective to the model predicted to be sensitive, as AZD6244 had
minimal effect on tumor growth in another PDX (i.e., EMCT2).
The response to AZD6244 in vivo was characterized by suppres-
sion of ERK1/2 phosphorylation and Ki67 in the sensitive model
EMC828, but not the comparator tumor EMCT2 (Figure 3I).
Consistent with these data, MEK treatment of xenografts re-
sulted in the suppression of RB phosphorylation and cell-cycle-
regulated proteins, as determined by reverse-phase protein
arrays (RPPAs) (Figure S3). Less dramatic single-agent re-
sponses observed in cell culture with multiple targeted agents
(IMD-0354, ABT-737, and CHIR125) were associated with
essentially no therapeutic response in corresponding PDX
models (Figure S3). These findings suggest that exceptional re-
sponses in cell culture are required in order to have therapeutic
impact on PDAC tumors in vivo and recapitulate the known ther-
apeutic recalcitrance of the disease.
Uncovering Effective Combination Therapies by
High-Throughput Screening
Combination therapies have the potential to increase the fre-
quency and duration of therapeutic response. However, rational
design of combination therapies remains difficult, due tos
sion correlation analysis revealed that the drug sensitivities across passages
el showed that distinct models harbored highly correlated responses to cancer
based on AUC. The agent color bar is associated with different drug classes as
stablished lines are noted in box-and-whisker plots, with statistical significance
models based on Euclidian distance. The EMC828 cell line exhibited a unique
at 100 nM, 250 nM, and 1 mM. The mean surviving fraction and SD are shown
ly significant as determined by unpaired t test. **p < 0.01; ***p < 0.001.
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inadequate understanding of individual targets, drug interac-
tions, and a paucity of biomarkers. Empirical approaches to
uncovering combination therapy sensitivities have proved suc-
cessful in defining new treatment strategies (Chen et al., 2012;
Crystal et al., 2014; Vora et al., 2014). To test this approach in
PDAC models, 14 clinically relevant drugs were evaluated in all
pairwise combinations across 11 different cell models at three
doses, yielding a total of 5,880 sensitivity measures (Figure 4A;
Data S2). These analyses defined a unique pattern of sensitivity
or ‘‘barcode’’ for each tumor model (Figures 4A and S4). In some
cases, low-dose responses to combination therapy increased
existing monotherapy sensitivity. For example EMC7310 was
sensitive to dasatinib, but this sensitivity was augmented by
multiple additional agents. However, there were many combina-
tions that could not be predicted from single-agent sensitivities,
and, surprisingly, PI3K (phosphatidylinositol 3-kinase) inhibitors
(BYL719 and GDC0941) had little positive impact in combina-
tion with any other agent (Figure 4B; Data S2). To evaluate
combinatorial potency, multi-drug dose-response analyses
were conducted and uncovered model-selective synergistic
drug interactions (Figures 4C and S4; Data File S2). These data
underscore the diversity of therapeutic response and indicate
that, in spite of using multiple combinations, there were no uni-
versal vulnerabilities in PDAC; however, subsets of cases were
sensitive to select combination treatments.
The robust responses to select combinations did not asso-
ciate with common genomic lesions (e.g., KRAS, TP53,
SMAD4) present in models (data not shown), nor did they corre-
spond to previously described predictive markers. For example,
the ratio of MCL1/NOXA implicated in resistance to ABT737
could not predict response to ABT737 in combination with
chemotherapy (Geserick et al., 2014). Based on these results,
gene expression features were explored relative to the response
to select combination treatments. Analysis of the top upregu-
lated and downregulated genes revealed a relatively broad
spectrum of deregulated biological processes. The elastic-net
method was used to more stringently define genes that were
positively or inversely correlated with the combinations tested.
These combined approaches yielded few genes that were repro-
ducibly associated with combinatorial sensitivities (Figure S4).
Unfortunately, data from clinical studies using the tested combi-
nations are not available to validate the performance of the po-Figure 3. Exceptional Response to MEK Inhibition
(A) Dose-response analysis of EMC828 versus EMC29 and EMC1222 cell-line mo
(B) Immunoblot analysis of the indicated proteins in the models treated with 0, 0
(C) The published KRAS dependence signature was subjected to supervised clu
(D) The suppression of bromodeoxyuridine (BrdU) incorporation and the induct
concentrations of AZD6244 (0, 0.25, and 1 mM). Mean and SD are shown from thre
by unpaired t test; ***p < 0.001.
(E) Representative crystal violet staining for cell viability in the indicated cell lines
(F) Representative micrographs of the EMC828 model grown as an organoid in 3D
from three independent cultures were subjected to increasing doses of AZD624
(G) The EMC828 xenograft was randomized to treatment with vehicle (n = 5) or A
shown; statistical significance was determined by ANOVA.
(H) Tumor weight from the indicated PDX models treated with vehicle or AZD624
t test. Error bars indicate SD.
(I) Representative immunohistochemical images of pERK1/2 and Ki67. Scale bars
ten high-power fields are shown. Statistical analysis was by unpaired t test. ***ptential biomarkers, which underscores the challenge associated
with developing predictive markers for combination therapies.
Tumor-Selective Trametinib Combinatorial Sensitivity
Translates to Disease Control In Vivo
Among the agents tested, the MEK inhibitor trametinib exhibited
potent combination activity with several agents (i.e., dasatinib,
docetaxel, and everolimus) and served as the backbone for a trial
of cell-line-encoded differential combinatorial sensitivities (Fig-
ure 5A). Trametinib, in combination with dasatinib, was effective
in several models, including EMC7310 and EMC29 (Figure 5B). In
these models, trametinib alone induced compensatory tyrosine
phosphorylation events that were blocked by dasatinib and
associated with increased apoptosis (Figures 5C–5E). These
effects translated into control of tumorigenic growth in the
corresponding PDX that, based on cell-line data, would be
predicted to be sensitive to this combination (Figure 5F). In
contrast, another PDXmodel that would be predicted to be resis-
tant to this combination failed to respond (Figure S5). Analysis of
sensitive PDX tissues confirmed suppression of p-ERK1/2,
p-Src, tyrosine phosphorylation, and the induction of apoptosis
(Figure 5G).
The combination of trametinib with docetaxel was the most
potent treatment identified in cell-line screening, with synergistic
interaction observed in several models (Figure 6A). In xenograft
assays, this combination potently suppressed tumor growth for
more than 30 days in two PDX models (Figures 6B and S6). In
contrast, single-agent treatments with docetaxel or trametinib
were insufficient to prevent rapid disease progression (Figures
6B and S6). Analysis of PDX tissue showed that MEK inhibition
generally limited proliferation and that docetaxel elicited cell
death, while the combination yielded adual response (Figure 6C).
To determine whether this therapeutic sensitivity was selective,
the same treatment was deployed against two PDXs models
that would be predicted, based on the cell-line data, to be resis-
tant. In these models, there was veritably no response to the
treatment (Figures 6D and 6E). These data indicate that thera-
peutic sensitivities identified in the primary cell lines translate
into responses in PDX derived from the same primary tumor.
To further interrogate the idea that sensitivities are model and
combination specific, the EMC519 PDX (resistant to trametinib +
docetaxel and trametinib + dasatinib combinations but sensitivedels exposed to AZD6244. Average and SD are shown from three experiments.
.25, and 1 mM AZD6244.
stering based on the exceptional response versus resistance.
ion of apoptosis were determined for the indicated cell lines, with increasing
e independent experiments. p value relative to vehicle control was determined
exposed to AZD6244. CTRL, control.
culture. Images were taken at 43; scale bars, 1 mm. Cells grown in 3D and 2D
4, and viability was determined. Mean and SD are shown.
ZD6244 (n = 5) until the control arm became moribund. The mean and SEM is
4 was determined at sacrifice. Statistical analysis was determined by unpaired
, 100 mm. Quantification of the staining and the average and SD frommore than
< 0.001.
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Figure 4. Combination Treatments
(A) Representation of drug sensitivity to combi-
nation treatment. The sensitivity of all treatments
was graphed, and the color bar indicates fractional
survival relative to DMSO control.
(B) Heatmap clustering the AUC values of effective
combinations in at least one of the cell lines. Cell
lines and combinations were clustered based on
Euclidean distance.
(C) Representative dose-response analysis of the
trametinib and dasatinib combination in a model
that yielded synergistic toxicity. Value shown in the
heatmap is percent survival minus 100 (i.e., 0 in-
dicates no effect on survival; 100 indicates
complete lack of survival).
2024 Cell Reports 16, 2017–2031, August 16, 2016
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Figure 5. Combinatorial Sensitivity to Dasatinib with Trametinib
(A) Combination treatment response barcode from a cell line that is sensitive to dasatinib and trametinib combination.
(B) Representative dose-response analysis of the trametinib-dasatinib combination in models that yielded synergistic toxicity. Value shown in the heatmap is
percent survival minus 100 (i.e., 0 indicates no effect on survival;100 indicates complete lack of survival), and the combination index for two cell lines is shown.
(C) Representative immunoblot analysis of the indicated proteins in the sensitive model exposed to the indicated agents: trametinib, 100 nM; dasatinib, 100 nM;
combination, 50 nM of each agent.
(D) Induction of cell death as a function of drug treatment from three independent cultures. The average and SD are shown; statistical analysis was by t test
comparing the combination to single-agent dasatinib treatment. **p < 0.01; ***p < 0.001.
(E) Representative 43 micrographs of cells on plates treated with the indicated drugs (scale bars, 1 mm).
(F) The PDX was randomized to treatment with vehicle control (n = 5) or the combination of trametinib and dasatinib (n = 5). The average tumor volume and SEM
are plotted. Mice were sacrificed when the control arm became moribund; statistical significance was determined by ANOVA.
(G) Representative staining of the indicated markers by immunohistochemistry. Scale bars, 100 mm.to trametinib + everolimus in cell-line screens) was treated with
trametinib and everolimus (Figure 6F). This combination yielded
measurable control of the PDX tumor growth (Figure 6F).
Together, these data suggest that cell models could be used
to infer drug sensitivities to direct the combinatorial treatments.
Model-Guided Chemotherapy Regimens
In the analysis of the combination drug screening data, it was
apparent that select targeted agents cooperate with chemo-therapy. As shown, the BCL2 inhibitor ABT737 and the check-
point kinase inhibitor AZD7762 resulted in model-specific
augmentation of the response to either gemcitabine or docetaxel
(Figures 7A–7C). ABT737 was particularly potent when com-
bined with gemcitabine or docetaxel in the EMC29 and
EMC3226 lines, respectively (Figures 7B and 7C). In contrast,
AZD7762 impacted on a separate collection of cell lines.
These data suggest underlying cellular vulnerabilities to
apoptotic or cell-cycle checkpoint inhibitors. The response toCell Reports 16, 2017–2031, August 16, 2016 2025
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the combination of ABT737 and gemcitabine was synergistic in
two cell models (Figure 7D) and, in PDX, translated to stable dis-
ease that was associated with a modest effect of therapy on
proliferation but a robust induction of apoptosis (Figure 7E).
Similarly, the combination of AZD7762 with gemcitabine yielded
disease control in the PDXmodel, and the response was accom-
panied by extensive DNA damage (Figure 7F). Together, these
data similarly illustrate that combinations with chemotherapy
can be effective but must be directed.
DISCUSSION
PDAC has a particularly poor prognosis, and even with new tar-
geted therapies and chemotherapy, the survival is poor. Here,
we show that patient-derived models can be developed and
used to investigate therapeutic sensitivities determined by ge-
netic features of the disease and to identify empirical therapeutic
vulnerabilities. These data reveal several key points that are of
prime relevance to pancreatic cancer and tumor biology in
general.
The Challenges of Using Genetic Analysis to Inform
Treatment in PDAC
Precision oncology is dependent on the existence of known vul-
nerabilities encoded by high-potency genetic events and drugs
capable of exploiting these vulnerabilities. At present, the reper-
toire of actionable genetic events in PDAC is limited. Rare BRAF
V600E mutations are identified in PDAC and could represent the
basis for targeted inhibition, as our group and others have previ-
ously published (Collisson et al., 2012; Witkiewicz et al., 2015).
Similarly, germline BRCA deficiency is the basis for ongoing
poly(ADP-ribose) polymerase (PARP) inhibitor clinical trials
(Lowery et al., 2011). As shown here, out of 28 cases, only one
genetic event was identified that yielded sensitivity to a thera-
peutic strategy. In this case, existence of the matched model
allowed us to confirm the biological relevance of the STAG2 mu-
tation by showing sensitivity of the model to a DNA cross-linking
agent. Therefore, annotated patient-derived models provide a
substrate upon which to functionally dissect the significance of
novel and potentially actionable genetic events that occur within
a tumor.
Another challenge of genomics-driven personalized medicine
is assessing the effect of specific molecular aberrations on ther-
apeutic response in the context of complex genetic changes
present in individual tumors. For example, KRAS has been pro-
posed to modify therapeutic dependency to EZH2 inhibitors
(Kim et al., 2015), and in the models tested, responses to thisFigure 6. Patient-Selective Targeting of Trametinib Combinations
(A) Dose-response analysis of combination treatment, indicating the synergisti
heatmap is percent survival minus 100 (i.e., 0 indicates no effect on survival; 1
(B) The PDX was randomized to treatment with single-agent trametinib (n = 4) or d
the mean and SEM are shown. Mice were sacrificed when the single-agent mice
(C) Representative immunohistochemistry and quantification. The average and S
t test. **p < 0.01; ***p < 0.001, relative to the vehicle control. Scale bars, 100 mm
(D and E) Two independent PDX models that were predicted to be resistant to
indicate SEM.
(F) Dose-response analysis of combination treatment, indicating the synergistic in
docetaxel. Response of the PDX to trametinib and everolimus treatment (n = 5 pclass of drugs were not uniformly present in cases harboring mu-
tations in chromatin-remodeling genes. This finding suggests
that, although tumors acquire genetic alterations in specific
genes, the implicated pathway may not be functionally inactive
or therapeutically actionable. Therefore, annotated patient-
derived models provide a unique test bed for interrogating spe-
cific therapeutic dependencies in a genetically tractable system.
Empirical Definition of Therapeutic Sensitivities and
Clinical Relevance
Cell lines offer the advantage of the ability to conduct high-
throughput approaches to interrogate many therapeutic agents.
A large number of failed clinical trials have demonstrated the dif-
ficulty in treating PDAC. Based on the data herein, the paucity of
clinical success is, most probably, due to the diverse therapeutic
sensitivity of individual PDAC cases, suggesting that, with an un-
selected patient population, it will be veritably impossible to
demonstrate clinical benefit. Additionally, very few models ex-
hibited an exceptional response to single agents across the
breadth of a library encompassing 305 agents. We could identify
only one tumor that was particularly sensitive to MEK inhibition
and another model that was sensitive to EGFR and tyrosine ki-
nase inhibitors.
In contrast to the limited activity of single agents, combination
screens yielded responses at low-dose concentrations in the
majority of models. Specific combinations were effective across
several models, indicating that, by potentially screening more
models, therapeutic sensitivity clades of PDAC will emerge. In
the pharmacological screens performed in this study, MEK inhi-
bition, coupled with MTOR, docetaxel, or tyrosine kinase inhibi-
tors, was effective in 30% of models tested. Resistance to
MEK inhibitors occurs through several mechanisms, including
upregulation of oncogenic bypass signaling pathways such as
AKT, tyrosine kinase, or MTOR (mammalian target of rapamycin)
signaling. In the clinic, the MEK and MTOR inhibitors (e.g.,
NCT02583542) are being tested. An intriguing finding from the
drug screen was sensitivity of a subset of models to combined
MEK and docetaxel inhibition. This combination has been
observed to synergistically enhance apoptosis and inhibit tumor
growth in human xenograft tumor models (Balko et al., 2012;
McDaid et al., 2005) and is currently being tested in a phase III
study in patients with KRAS-mutated, advanced non-small-cell
lung adenocarcinoma (Ja¨nne et al., 2016). Interestingly, in the
models tested herein, there was limited sensitivity imparted
through the combination of gemcitabine and MEK inhibition.
This potentially explains why the combination of MEK inhibitor
and gemcitabine tested in the clinic did not show improvedc interaction of trametinib and docetaxel in two models. Value shown in the
00 indicates complete lack of survival).
ocetaxel (n = 4), or the combination (n = 5). Tumor volume was measured, and
became moribund or at the end of 33 days of treatment.
D are shown from at least three tumors. Statistical analysis was by unpaired
.
trametinib + docetaxel failed to respond to treatment. p > 0.05. Error bars
teraction of trametinib and everolimus from a model resistant to trametinib and
er arm). Tumor volume was measured, and the mean and SEM is shown.
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Figure 7. Differential Cooperation of Apoptotic and Cell-Cycle Checkpoint Inhibitors with Chemotherapy
(A) Heatmap showing the AUC of single and combination treatments with ABT737 or AZD7762 and chemotherapy. Cell lines and drugs were clustered based on
Euclidian distance.
(B) Relative survival of the indicated cell lines treated with increasing concentrations (25, 84, and 250 nM) of gemcitabine or docetaxel, as measured in triplicate
from two independent experiments.
(legend continued on next page)
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efficacy over gemcitabine alone (Infante et al., 2014). Another
promising strategy that emerged from this study involves using
CHK or BCL2 inhibitors as agents that drive enhanced sensitivity
to chemotherapy. Together, the data suggest that the majority of
PDAC tumors have intrinsic therapeutic sensitivities, but the
challenge is to prospectively identify effective treatment.
Patient-Derived Model-Based Approach to Precision
Medicine
This study supports a path for guiding patient treatment based
on the integration of genetic and empirically determined sensitiv-
ities of the patient’s tumor (Figure S7). In reference to defined ge-
netic susceptibilities, the models provide a means to interrogate
the voracity of specific drug targets. Parallel unbiased screening
enables the discovery of sensitivities that could be exploited in
the clinic. The model-guided treatment must be optimized, al-
lowing for the generation of data in a time frame compatible
with clinical decision making and appropriate validation. In the
present study, the majority of models were developed, cell lines
were drug screened, and select hits were validated in PDX
models within a 10- to 12-month window (Figure S7). This chro-
nology would allow time to inform frontline therapy for recurrent
disease for most patients who were surgically resected and
treated with a standard of care where the median time to recur-
rence is approximately 14 months (Saif, 2013). Although most
models were generated from surgically resected specimens,
two of the models (EMC3226 and EMC62) were established
from primary tumor biopsies, indicating that this approach could
be used with only a limited amount of tumor tissue available. In
the context of inoperable pancreatic cancer, application of
data from a cell-line screen without in vivo validation in PDX
would permit the generation of sensitivity data in the time frame
compatible with treatment. We acknowledge that model-guided
treatment is also not without significant logistical hurdles,
including the availability of drugs for patient treatment, clinically
relevant time frames, patient-performance status, toxicity of
combination regiments, and quality metrics related to model
development and therapeutic response evaluation. Additionally,
it will be very important to monitor ex vivo genetic and pheno-
typic divergence with passage and try to understand the features
of tumor heterogeneity that could undermine the efficacy of
using models to direct treatment. As shown here, drug sensitiv-
ities remained stable with passage in cell culture and, impor-
tantly, were confirmed in PDX models, suggesting that the
dominant genetic drivers and related therapeutic sensitivities
are conserved.(C) Relative survival of the indicated cell lines treated with increasing concentrat
triplicate from two independent experiments.
(D) Summary of the cooperation between ABT737 and gemcitabine in a sensitive m
synergistic interaction in the EMC29 model and related cooperative index. Value
survival; 100 indicates complete lack of survival).
(E) The PDX was randomized to treatment with vehicle control (n = 3) or gemcitab
volume and SEM are plotted. Mice were sacrificed when the control arm became
staining and quantitation of the indicated markers by immunohistochemistry. Th
unpaired t test. *p < 0.05; **p < 0.01.
(F) A PDX model sensitive to AZD7762 and gemcitabine was treated singly or in c
and statistical significance was determined by ANOVA. Representative gH2AX s
Error bars indicate SD in (B) and (C) and SEM in (F).In spite of these challenges, progressively more effort is
going into the development of patient-derived models for
guidance of disease treatment (Aparicio et al., 2015; Boj
et al., 2015; Crystal et al., 2014; van de Wetering et al.,
2015). Several ongoing trials use PDX models to direct a limited
repertoire of agents (e.g., NCT02312245, NCT02720796, and
ERCAVATAR2015). Given the experience here, PDAC cell lines
would provide the opportunity to rapidly interrogate a larger
portfolio of combinations that could be used to guide patient
care and provide a novel approach to precision medicine.
Validation of this approach would require the establishment
of challenging multi-arm or N-of-1 clinical trials. However,
considering the dire outcome for PDAC patients and the
long-lasting difficulty in developing effective treatments, this
non-canonical approach might be particularly impactful in
pancreatic cancer.
EXPERIMENTAL PROCEDURES
Cell Culture and PDX
Tumor tissue acquisition was performed under an Institutional Review Board
(IRB) protocol approved at the University of Texas Southwestern Medical
Center and Ochsner Clinic. Informed written consent was obtained from all
patients. PDX models were developed and utilized in accordance with Institu-
tional Animal Care and Use Committee approved protocols at UT South-
western Medical Center. Primary cell models were established and cultured
on collagen-coated tissue culture plates in supplemented KSF media. Cells
were passaged by trypsinization and used at early passage (p < 5) and late
passage (p > 20) for the analysis of drug sensitivity. Established cell lines
were from the ATCC and cultured using published methodology. The detailed
description of these models will be published elsewhere, but the description
of the derivation approach is provided in the Supplemental Experimental
Procedures.
Drug Treatments
Cell models were subjected to drug screeningwith libraries, combination treat-
ments, and single agents, as summarized in the Supplemental Experimental
Procedures. The treatment of PDXmodels was in accordancewith institutional
animal care and use committee (IACUC) protocols at the University of Texas
Southwestern Medical Center and is summarized in the Supplemental Exper-
imental Procedures.
Immunohistochemistry and Model Analysis
Immunohistochemistry was performed on a DAKO stainer using conditions as
described in the Supplemental Experimental Procedures. Immunoblotting,
immunofluorescence, RPPA analysis, flow cytometry, and other methods
were performed using standard procedures. The specific features of the
experimentation are provided in the Supplemental Experimental Procedures.
RNA sequencing was performed on an Illumina instrument with paired-end
reads.ions (25, 84, and 250 nM) of the indicated drug combinations as measured in
odel. Dose-response analysis of combination treatments, indicating selective
shown in the heatmap is percent survival minus 100 (0 indicates no effect on
ine and ABT737 (n = 8), and tumor volume was determined. The average tumor
moribund. Statistical significance was determined by ANOVA. Representative
e average and SD are shown. Scale bars, 100 mm. Statistical analysis was by
ombination (n = 5 per arm). Tumor volume was measured as a function of time,
taining is shown (scale bars, 50 mm).
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